...
Value proposition and use:
>Need well curated, more diverse (different animal models, different Abs, etc.) and evolving data on reference molecules (- this is already available internally but to a lesser extent)..
>Use the dataset to improve the likelihood of developing new predictive models
>Use the dataset for better standardisation; allowing for robust comparison, cross referencing, identifying outliers and further analyses.
>Use the dataset to link early screening data to later (endpoint) data.>Use the dataset to cross reference and pick outliers.
Scope:
>Initial focus is on mAbs
>Include information on ADCs (this needs to be contextualised in the database)
>Other IgG-like molecules to be included based on absence of technical limitations
Approach:
>'Gold standard' dataset defined as one which allows the direct comparison of different studies and contains a minimum set of required parameters.
>Collate PK on 10 priority marketed Ab drugs which are know to have high quality published data and check whether this meets the above definition.
>Propose 'data quality' tiers into which data from published molecules can be placed.
...